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Background: Published studies have reported conflicting results regarding the effects of cinnamon on glucose,
lipids and insulin. To gain further insight into the metabolic effects of Cinnamomum cassia we performed
randomized, double-blinded placebo-controlled study using euglycaemic-hyperinsulinaemic clamp.
Methods: Twenty-one subjects with impaired glucose tolerance (IGT) were included in the study (10 or 11 subjects
in each group). The study groups were matched for age, gender and body mass index (BMI). Waist-to-hip ratio, BMI,
blood pressure, fasting blood glucose, insulin, triglycerides, total cholesterol, low-density lipoprotein, high-density
lipoprotein , HbA1c, ASAT, ALAT, bilirubin, ALP, GT and PK were measured before and after the intake of capsules
equivalent to 6 g cinnamon twice a day for 12 weeks. The changes in insulin resistance were measured by
euglycaemic-hyperinsulinaemic clamp. The Wilcoxon signed rank sum test, the Mann-Whitney U test and Pearson’s
chi-squared test were used to analyse the data. Values of p < 0.05 were considered to indicate statistically significant
differences.
Results: At enrolment, the groups were similar in terms of age, gender and BMI. Of the 21 randomized patients
with IGT, 17 completed the study (8 controls vs. 9 treated). The ingestion of 6 g cinnamon twice a day for 12 weeks
had no significant effect on insulin sensitivity, HbA1c, fasting glucose or BMI. No significant changes were seen in
lipids or liver enzymes.
Conclusions: This study showed that ingestion of 6 g C. cassia twice a day for 12 weeks did not change the insulin
sensitivity or liver enzymes in subjects with IGT.Background
Chronic diseases such as cardiovascular disease, cancer,
chronic respiratory disease and diabetes mellitus are cur-
rently the major cause of death in almost every country
worldwide, and not only in the developed countries.
According to the World Health Organization chronic
diseases cause almost 35 million deaths each year world-
wide, which is 60% of the total mortality. Cardiovascular
diseases account for almost 50% of deaths due to
chronic diseases [1]. The aging population and changes
in lifestyle, such as increased energy intake and de-
creased physical activity, are becoming a growing prob-
lem, resulting in an increase in the incidence of obesity* Correspondence: joanna.hlebowicz@med.lu.se
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article, unless otherwise stated.and diabetes. Over the past three decades, the preva-
lence of diabetes mellitus has more than doubled. It has
been estimated that the number of people with diabetes
worldwide will rise from 6.4% in 2010 (285 million
people) to 7.7% (439 million people) by 2030 [2], and
the number of obese individuals is projected to rise from
33% (1.3 billion) in 2005 to 57.8% (3.3 billion) in 2030
[3]. Diabetes and obesity are two major risk factors for the
development of cardiovascular disease, and the above pre-
dictions indicate that cardiovascular disease will soon
reach epidemic proportions. It is still not completely
understood why diabetes is one of the major risk factors
for coronary heart disease, but it has been hypothesized
that hyperglycaemia triggers an inflammatory response in
the vessels and that inflammation leads to atherosclerosis.
Seventy-five to eighty per cent of deaths in adult diabetics
are related to cardiovascular disease [4].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Clinical and demographic characteristics of the
subjects with IGT at baseline
Variables Controls Treated
Subjects 8 9
Female/Women 5 (63) 5 (56)
Male/Men 3 (37) 4 (44)
Age (years) 72 ± 2 73 ± 2
BMI (kg/m2) 28.6 ± 1.9 25.7 ± 1.3
Waist circumference (cm) 0.9 ± 0.1 0.9 ± 0.09
Smoking
No 8 (100) 6 (67)
Previously 0 (0) 3 (33)
Present 0 (0) 0 (0)
Blood pressure
Systolic (mmHg) 122 ± 16.7 140.5 ± 4,7
Diastolic (mmHg) 80.0 ± 2.6 82.0 ± 2.8
Fasting-glucose (mmol/l) 6.7 ± 0.4 6.0 ± 0.3
Fasting-insulin (mlE/l) 11.1 ± 2.0 9.8 ± 2.1
HbA1c (mmol/mol) 40.1 ± 2.4 39.6 ± 1.3
Cholesterol (mmol/l) 4.5 ± 0.2 4.9 ± 0.4
LDL Cholesterol (mmol/l) 2.7 ± 0.2 3.2 ± 0.4
HDL Cholesterol (mmol/l) 1.5 ± 0.1 1.4 ± 0.1
Triglycerides (mmol/l) 1.1 ± 0.1 1.1 ± 0.1
Gender and smoking-related values are given as percentages, all other values
are reported as the mean ± SD.
The groups did not differ for any variable, p<0.05.
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http://www.nutritionj.com/content/13/1/96Impaired glucose tolerance (IGT) is the term used to
describe the intermediate stage between normal glucose
metabolism and type 2 diabetes mellitus. Subjects with
IGT have an increased risk of developing type 2 diabetes
mellitus and cardiovascular disease compared with
normoglycaemic subjects, and early interventions are,
therefore, important. The causes of type 2 diabetes mel-
litus are multifactorial, but diet plays an important role
in the incidence, severity and management of the condi-
tion [5]. The relationship between dietary factors and
coronary heart disease has been studied previously, and
it has been found that dietary interventions that reduce
the level of circulating blood sugar can reduce the risk
of developing diseases such as type 2 diabetes mellitus
and cardiovascular disease, which are the two major risk
factors for early death [5].
Various types of natural remedies have been used
historically for the treatment of ailments, among them
Cinnamomum cassia. C. cassia is obtained from the bark
of the outer skin of a tall evergreen tree, and contains
active components including cinnamic aldehyde, cinna-
myl aldehyde, tannin, mucus and carbohydrates. These
components have been found to have anti-oxidant,
anti-microbial, anti-inflammation, anti-diabetic and anti-
tumour activity [6-8]. C. cassia and C. zeylanicum ex-
tracts have been shown to be among the most effective
natural substances in the regulation of blood glucose [9].
However, some studies have shown that coumarin,
found in C. cassia, may have detrimental effects on the
liver, and the Federal Institute for Risk Assessment in
Europe has, therefore, suggested that it be replaced by
C. zeylanicum [10]. We have previously shown that the
ingestion of 6 g C. cassia powder reduces the postpran-
dial blood glucose concentration [11]. However, in a
later study, we found that the ingestion of C. zeylanicum
did not affect postprandial blood glucose or insulin
levels in humans [12].
Other studies have shown conflicting results regarding
the effect of cinnamon on insulin sensitivity, when mea-
sured indirectly [13-16]. In the present study, we investi-
gated whether C. cassia increased insulin sensitivity in
subjects with IGT, using the euglycemic-hyperinsulinaemic
clamp, which provides a direct measure of insulin resist-
ance. To the best of our knowledge, the direct measure-
ment of the effect of cinnamon on insulin resistance been
not been studied previously in humans. We also investi-
gated whether C. Cassia supplementation had any effect on
liver enzymes.
Subjects and methods
Twenty-one subjects with IGT, who met the study cri-
teria, were included in this randomized, double-blinded
placebo-controlled study. The inclusion criterion was
diagnosis of IGT, by a standard 75 g OGTT, for less than12 months before enrolment. Glucose tolerance status
and fasting blood glucose levels were evaluated using
the criteria established by the WHO [5]. The exclusion
criteria were: thyroid disorders, or insulin, oral hypo-
glycaemics, or insulin-sensitizing drugs within 60 days
before enrolment. The subjects were recruited from
the population in southern Sweden and all examina-
tions were done in the same institution. After diagnosis
of IGT, all participants lifestyle advice but no medica-
tions. Four subjects dropped out of the study, one for
personal reasons (treated group), one had difficulty
swallowing the capsules (control group), and two had
gastrointestinal problems (control group). These four
subjects did not differ from the 17 participants at base-
line. Patients were allocated to the treatment or control
group using stratified randomized selection for age, sex
and body mass index (BMI) (Table 1). They were ran-
domly selected to either the A or B group by sealed
envelopes.
All the capsules were prepared in advance by Scandi-
navian Nutrients AB (Strängnäs, Sweden), and contained
either 700 mg cellulose or 500 mg C. cassia and 200 mg
cellulose. Participants received both individual verbal
and written information and signed a consent form. The
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morning at breakfast time and one each evening at din-
ner time for 12 weeks. During this period, the subjects
were examined three times, at baseline, after sex weeks
and finally, after 12 weeks. Insulin sensitivity was mea-
sured at baseline and after 12 weeks, in the morning
after a 12-hour fast. Smoking and snuff-taking were pro-
hibited 8 hours prior to and during the test.
Insulin sensitivity was determined with the euglycaemic-
hyperinsulinaemic clamp, according to DeFronzo et al.
[17]. Intravenous catheters were inserted into antecubital
veins in both arms. One arm was used for the infusion of
glucose and insulin, and the contralateral arm was used
for blood intermittent sampling. The catheter was kept pa-
tent by a slow infusion of 0.9% saline, to which 2 ml of the
subject’s blood per 100 ml infusate had been added to pre-
vent the absorption of insulin to glassware and plastic sur-
faces. Baseline samples of glucose and insulin were taken.
A primed constant infusion of insulin (Actrapid 100 IU/
ml; NovoNordisk, Bagsvaerd, Denmark), was started at a
constant infusion rate of 0.28 nmol/m2 body surface area/
min. After 4 min, glucose infusion (200 mg/ml) was started;
the infusion rate being adjusted manually throughout
the procedure to maintain the blood glucose level at
5.0 mmol/l. Blood glucose was determined at the bedside
every 5 minutes. Blood samples were taken after 60 and
120 min for the analysis of the insulin concentration. Blood
glucose concentrations were measured with the HemoCue
Glucose system (HemoCue AB, Ängelholm, Sweden). The
precision of the HemoCue Glucose system was better than
0.3 SD in the range 0 mmol/l to 22.2 mmol/l.
All analyses of plasma and whole blood were per-
formed on samples obtained after overnight fasting.
Analyses of fasting plasma triglycerides, total cholesterol,
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), HbA1c, ASAT, ALAT, bilirubin, ALP, GT, PK,
whole-blood glucose (fasting blood glucose), and insulin
were carried out at the time of baseline examination, at
the Department of Clinical Chemistry, Skane University
Hospital in Malmö, which is affiliated to a national
standardization and quality control system. Insulin con-
centrations were measured using an immunoassay with
an alkaline phosphatase conjugate (Access Ultrasensitive
Insulin, Beckman-Coulter AB, Bromma, Sweden). The
sensitivity of the insulin immunoassay was 0.03 mU/l,
and the intra-assay coefficient of variation was less than
10% in the range 0.03 mU/l to 300 mU/l. Total choles-
terol and HDL were measured by enzyme assay kits,
using an automated analyser (Aeroset™, Abbott Labs,
USA). LDL was calculated using the Friedewald equation
[18]. All samples from each subject were analysed in the
same run.
The study was approved by the Ethics Committee of
Lund University and was performed according to theHelsinki Declaration. The study started in 2011 and was
completed in 2013.
All statistical calculations were performed using SPSS
for Windows software (version 22, 2013). The Wilcoxon
signed rank sum test was used to compare quantitative
variables within the group, and the Mann-Whitney
U test was used to compare quantitative variables be-
tween groups. Pearson’s chi-squared test for categorized
variables was used to test for statistical significances be-
tween the groups. Values of p < 0.05 were considered to
indicate statistically significant differences.
Results
No significant changes were seen in clinical or demo-
graphic characteristics such as BMI, waist:hip ratio, sys-
tolic or diastolic blood pressure between the two groups
at baseline (Table 1). No significant differences were
found in HbA1c, fasting blood glucose or insulin levels
at baseline, but the placebo group had a significantly
lower fasting insulin level after 12 weeks (Table 2). No
significant differences were seen in total cholesterol,
LDL cholesterol, HDL cholesterol, triglycerides at base-
line, and there were no significant changes during the
study (Table 2). Neither were any significant changes
seen in ALAT, ALP, GT or bilirubin (Table 2). No sig-
nificant increase in insulin sensitivity was seen in the
treated group after 60 or 120 min (Table 3). In the pla-
cebo group, a significant increase in insulin sensitivity
was seen at 60 min, but not at 120 min.
Discussion
In this study, it was found that 12 weeks of C. cassia
supplementation (12 g/d) did not improve fasting plasma
glucose, insulin, blood lipids or insulin sensitivity in pa-
tients with IGT. Neither were any of the liver enzymes
affected in this study. Although the effects of cinnamon
on glucose, insulin resistance and lipid profile have been
investigated in several studies, showing conflicting re-
sults, to the best of our knowledge, this is the first study
to use a direct measurement of insulin resistance.
Cinnamon has demonstrated qualities that enhance
glucose uptake by activating insulin receptor kinase ac-
tivity, autophosphorylation of the insulin receptor, and
glycogen synthase activity, in vitro and in vivo [19-22].
In a study on patients with type 1 diabetes who were
given cinnamon (unknown species) no differences were
found in HbA1c, total daily insulin intake, or number of
hypoglycaemic episodes, compared to the placebo group
[23]. This may be explained by the fact that cinnamon
decreases insulin resistance, which is not the cause of
type 1 diabetes. Insulin resistance plays a key role in the
development of diabetes, and cinnamon may have qual-
ities that decrease insulin resistance. However, this has
not been verified in humans using direct measurements,
Table 2 Glycemic outcomes, lipids and liver enzymes in patients with IGT, at baseline and after 12 weeks’ treatment or
placebo
Variables Baseline 12 wk.
Control Treated p-value Control p-value Treated p-value
Fasting-glucose (mmol/l) 6.7 ± 0.4 6.0 ± 0.3 0.370 6.1 ± 0.4 0.205 6.1 ± 0.4 0.735
Fasting-insulin (mlE/l) 11.1 ± 2.0 9.8 ± 2.1 0.481 8.5 ± 1.6 0.034* 9.0 ± 2.5 0.284
HbA1c (mmol/mol) 40.1 ± 2.4 39.6 ± 1.3 0.815 40.1 ± 1.8 0.786 40.2 ± 1.6 0.320
Cholesterol (mmol/l) 4.5 ± 0.2 4.9 ± 0.4 0.673 4.4 ± 0.2 0.670 4.6 ± 0.3 0.482
LDL Cholesterol (mmol/l) 2.7 ± 0.2 3.2 ± 0.4 0.606 2.6 ± 0.3 0.528 2.9 ± 0.2 0.553
HDL Cholesterol (mmol/l) 1.5 ± 0.1 1.4 ± 0.1 0.888 1.5 ± 0.1 0.774 1.4 ± 0.1 0.414
Triglycerides (mmol/l) 1.1 ± 0.1 1.1 ± 0.1 0.888 1.0 ± 0.2 0.686 1.0 ± 0.1 0.101
ASAT (μkat/l) 0.38 ± 0.04 0.40 ± 0.05 0.888 0.38 ± 0.04 0.752 0.41 ± 0.05 0.445
ALAT (μkat/l) 0.39 ± 0.07 0.50 ± 0.09 0.481 0.38 ± 0.08 0.528 0.49 ± 0.09 0.799
ALP (μkat/l) 0.89 ± 0.05 1.04 ± 0.13 0.541 0.86 ± 0.06 0.161 1.10 ± 1.28 0.128
GT (μkat/l) 0.37 ± 0.07 0.58 ± 0.15 0.370 0.36 ± 0.06 0.674 0.71 ± 0.25 0.313
Bilirubin (μmol/l) 9.2 ± 1.1 9.9 ± 1.6 0.963 8.5 ± 1.1 0.197 11.6 ± 2.0 0.087
Pk (INR) 1.04 ± 0.02 1.0 ± 0.02 0.888 1.01 ± 0.02 0.157 1.0 ± 0.02 0.317
Significant differences between the control and treated group in glycemic outcomes, lipids and liver enzymes were evaluated at baseline with the Mann-Whitney
U test.
Significant differences within the groups in glycemic outcomes, lipids and liver enzymes were evaluated at 12 wk. with the Wilcoxons signed rank test, *p < 0.05.
Values are reported as means ± SD.
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tion in insulin resistance was seen in six nondiabetic
women after the intake of C. burmannii, 1 g per day, in
capsules, for 8 weeks [13]. A reduction in insulin resist-
ance was also reported in a recently published study in
which 23 patients with nonalcoholic fatty liver disease
were given 1.5 g cinnamon (unknown species) per day
for 12 weeks [14]. Solomon et al. found improved insulin
sensitivity in eight healthy men after a 14-day interven-
tion with C. cassia (pills, 3 g per day) [15]. However,
Vanschoonbeek et al. reported that insulin sensitivity
was not improved in twelve women with type 2 diabetes
mellitus after taking 1.5 g C. cassia per day for 6 weeks
[16]. In the studies mentioned above, insulin resistance
was measured using a homeostatic model assessment
(Homa-IR), the quantitative insulin sensitivity check index
(Quick) or the insulin sensitivity index (ISI) [24-26]. How-
ever, these provide indirect measures of insulin resistance.
Both Homa-IR and Quick provide quantitative measure-
ments based on fasting insulin and fasting glucose levels,Table 3 Insulin sensitivity measured by euglycaemic-hyperins
after 12 weeks’ treatment or placebo
Baseline 12 weeks p-val
Placebo (n = 8)
60 min 6.3 ± 1.2 8.8 ± 1.9 0.012
120 min 5.3 ± 1.8 7.0 ± 1.2 0.06
Significant differences in insulin sensitivity within the groups were evaluated at 60
* = Significant difference within the groups between 60 min resp. 120 min at baseli
Values are reported as means ± SD.while ISI is based on the oral glucose tolerance test. It has
been recognized that Homa-IR gives relatively low values
in patients with insulin resistance undergoing elective sur-
gery [27] or who have advanced type 2 diabetes mellitus
[28]. On the other hand, it has been reported in other
studies that Homa-IR shows good correlation with the ISI
assessed with the euglycaemic-hyperinsulinaemic clamp
[29]. Methods of assessing insulin sensitivity using an oral
glucose tolerance test have been proposed in a few studies
[30,31]. Although this indirect method of measuring insu-
lin resistance is simple and plays an important role in
large-scale studies, the golden standard in smaller studies
is the euglycaemic-hyperinsulinaemic clamp.
In 2003, Khan et al. reported remarkable results fol-
lowing the ingestion of 1, 3 and 6 g C. cassia powder per
day for 40 days. Not only were the levels of fasting glu-
cose reduced in subjects with type 2 diabetes mellitus,
but positive effects were also seen on triglyceride, LDL
and total cholesterol levels [31]. Following this study,
several other studies on subjects with type 2 diabetesulinaemic clamp in patients with IGT, at baseline and
ue Baseline 12 weeks p-value
C. cassia (n = 9)
* 7.3 ± 1.3 7.8 ± 1.4 0.477
8 6.0 ± 1.1 6.3 ± 0.9 0.373
min resp. 120 min at baseline and 12 wk. with the Wilcoxons signed rank test.
ne and at 12wk., *p < 0.05.
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with varying results. The study by Mang et al. [32] re-
vealed that 3 g C. cassia supplement per day for 4 weeks
reduced fasting glucose in type 2 diabetes mellitus pa-
tients. In contrast, Vanschoonbeek et al. and Blevins et al.
found no difference in fasting glucose in type 2 diabetes
mellitus patients after taking 1.5 g C. cassia per day for
6 weeks, and 1 g C. cassia per day for 12 weeks, respect-
ively [16,33]. No difference was observed in HbA1c, total
cholesterol, LDL, HDL or triglyceride concentrations in
any of the above studies [16,32,33]. A meta-analysis per-
formed in 2008 revealed no effect of ingested cinnamon
on glucose or lipid parameters in subjects with type 1 or
type 2 diabetes mellitus [34].
However, in a recent study, HbA1c was found to be
decreased in patients with type 2 diabetes mellitus (1 g
C. cassia per day for 12 weeks ) [35]. Similar results
were obtained by Akilen (2 g C. cassia per day for
12 weeks) and Lu (120 mg per day or 360 mg C. aroma-
ticum per day for 12 weeks) [36,37]. In these studies, the
subjects had HbA1c levels above 8% and high fasting
glucose levels, and were already using concomitant
hypoglycaemic medication. The subjects in this present
study had IGT, had normal HbA1c levels and were not
receiving any medication for diabetes. These results sug-
gest that individuals with poorly controlled diabetes may
benefit more from cinnamon intake than those receiving
adequate treatment. A new meta-analysis in 2013 of type
2 diabetes mellitus patients revealed a decrease in fasting
plasma glucose, HbA1c, total cholesterol, LDL and triac-
ylglycerol levels, and an increase in HDL, but no change
in HbA1c, after the ingestion of cinnamon [38]. These
conflicting results might be due to differences in pre-
scribed anti-diabetic medication, the type and dose of
cinnamon administered, the duration of the study, and/
or the population studied.
Coumarin is present in cinnamon, especially C. cassia.
Debate on the toxicity of coumarins started after experi-
mental studies on hepatotoxicity in dogs. The Federal
Institute for Risk Assessment issued a warning on the
consumption of cinnamon and established a limit of
0.1 mg coumarin per kg body weight/day. In a study on
114 participants who ingested 30 mg coumarin com-
bined with a vasoactive component, Schmeck-Lindenau
et al. found that nine of the patients showed elevated
levels of transaminases in serum [39]. But they con-
cluded that the risk of elevated transaminases was lim-
ited after risk factors, as hepatitis in the history and
other diseases in the liver were considered. In a bioki-
netic study, Abraham et al. showed that coumarin is well
absorbed from ingested C. cassia [40]. According to the
Federal Institute for Risk Assessment the average cou-
marin content in C. cassia is 3000 mg/kg. In our study,
where the subjects ingested 12 g C. cassia per day for12 weeks, i.e., about 36 mg coumarin, no significant
changes were seen in transaminases. Askari et al. found
a reduction in the level of transaminases in patients with
nonalcoholic fatty liver disease, who were given 1.5 g
cinnamon/day for 12 weeks [14]. Larger and long-term
studies are needed to elucidate the effect of coumarin in
hepatotoxicity.
The strengths of the present study were the double-
blind placebo-controlled design with few drop-outs, and
the direct measurement of insulin sensitivity. However,
this study also had some limitations. Firstly, the sample
size was small and all the participants were living in
southern Sweden. Secondly, the control group had a sig-
nificantly lower insulin response than the treated group
after 12 weeks, which indicates that the placebo capsules
had an active effect. The placebo capsules contained cel-
lulose, which is a type of fibre, and the amount of fibre
was probably sufficient to cause an effect on the gastro-
intestinal tract, leading to an indirect effect on insulin
response. The relation between high fibre diets and a
low insulin response is already known [41]. Thirdly, we
had no means of precisely determining the compliance,
but this was assessed by counting the remaining capsules
and repeated follow-ups. Finally, although the cinnamon
and placebo capsules appeared identical, it is possible
that some of the participants could discern a difference
between the two types of capsules because of the smell.
In conclusion, the findings of this study were that the
ingestion of 6 g C. cassia twice a day for 12 weeks did
not change the insulin sensitivity or liver enzymes in
subjects with IGT.
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